Kaleido Biosciences, Inc.
KLDO
$0.002
$0.00191,900.00%
OTC PK
| 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | |
|---|---|---|---|---|---|
| Revenue | 492.00K | 104.00K | 211.00K | 297.00K | 243.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 492.00K | 104.00K | 211.00K | 297.00K | 243.00K |
| Cost of Revenue | 15.57M | 17.41M | 17.63M | 17.19M | 14.34M |
| Gross Profit | -15.08M | -17.31M | -17.42M | -16.89M | -14.10M |
| SG&A Expenses | 4.62M | 5.11M | 5.79M | 5.46M | 5.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -145.00K | -- | -- | -- | 193.00K |
| Total Operating Expenses | 20.05M | 22.52M | 23.42M | 22.65M | 19.74M |
| Operating Income | -19.55M | -22.41M | -23.21M | -22.35M | -19.49M |
| Income Before Tax | -20.27M | -23.09M | -23.89M | -23.04M | -20.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.27M | -23.09M | -23.89M | -23.04M | -20.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.27M | -23.09M | -23.89M | -23.04M | -20.02M |
| EBIT | -19.55M | -22.41M | -23.21M | -22.35M | -19.49M |
| EBITDA | -18.95M | -21.82M | -22.62M | -21.77M | -18.93M |
| EPS Basic | -0.48 | -0.54 | -0.56 | -0.58 | -0.56 |
| Normalized Basic EPS | -0.30 | -0.34 | -0.35 | -0.36 | -0.35 |
| EPS Diluted | -0.48 | -0.54 | -0.56 | -0.58 | -0.56 |
| Normalized Diluted EPS | -0.30 | -0.34 | -0.35 | -0.36 | -0.35 |
| Average Basic Shares Outstanding | 42.60M | 42.58M | 42.54M | 39.69M | 35.98M |
| Average Diluted Shares Outstanding | 42.60M | 42.58M | 42.54M | 39.69M | 35.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |